Functional tricuspid regurgitation: Feasibility of transcatheter interventions

Abstract

Functional tricuspid regurgitation (TR) develops secondary to annular dilation and leafl et tethering as a result of right ventricular remodeling. Invasive surgery for isolated TR is rarely performed due to high inpatient mortality. Transcatheter tricuspid valve intervention is an appealing solution but is challenging as crucial structures are closely related to the tricuspid valve, and intracardiac devices pose further challenges to device delivery and implantation.

Transcatheter tricuspid valve replacement for functional tricuspid regurgitation after left‐sided valve surgery: A single‐center experience

“…It is important to note that due to the larger diameter of the native TA, a large-bore, flexible delivery system is necessary to accommodate a prosthesis that is approximately twice the size used in transcatheter aortic valve replacement. 16,31 T A B L E 4 Paired analyses of patient characteristics and echocardiographic parameters at baseline and follow-up. The LuX-Valve, an in situ TTVR device with radial force-independent fixation, has demonstrated effectiveness in previous clinical studies.…”

“…Additionally, these patients may have a larger right heart or a pacemaker lead impinging on the valve leaflet 18 . To minimize surgical complexity and reduce the risk of short‐term recurrence, transcatheter replacement is often considered a more suitable approach compared to transcatheter repair, considering the anatomical factors and maneuverability involved 16 . However, it is important to note that this preference for transcatheter replacement also presents significant challenges in terms of designing and operating TTVR systems.…”

“…In recent years, the utilization of transcatheter techniques to mimic TV surgery has made significant progress and holds promise for high-risk patients with FTR. [14][15][16][17] Nevertheless, it is crucial to recognize that different types of devices have specific indications to address this unmet clinical need. 14,16,18 In this study, we present the dedicated transcatheter tricuspid valve replacement (TTVR) device, the Lux-Valve (Ningbo Jenscare Biotechnology, Ningbo, China), and share our experiences of usage in patients with FTR after LSVS.…”

“…[14][15][16][17] Nevertheless, it is crucial to recognize that different types of devices have specific indications to address this unmet clinical need. 14,16,18 In this study, we present the dedicated transcatheter tricuspid valve replacement (TTVR) device, the Lux-Valve (Ningbo Jenscare Biotechnology, Ningbo, China), and share our experiences of usage in patients with FTR after LSVS. This patient population is considered high risk, and our goal was to provide insights into the outcomes and efficacy of this device.…”

“…In recent years, the utilization of transcatheter techniques to mimic TV surgery has made significant progress and holds promise for high‐risk patients with FTR 14–17 . Nevertheless, it is crucial to recognize that different types of devices have specific indications to address this unmet clinical need 14,16,18 .…”